multiple sclerosis (MS)
Mystery and Insurability: Unraveling the Challenge of Multiple Sclerosis
It may become even more challenging to underwrite applicants with Multiple Sclerosis (MS), and that is positive news for patients. Medical advances are outpacing mortality data so swiftly that, within the decade, it could be possible for the majority of applicants to be prescribed medications for which there are currently no long-term experience studies.
Presentations from the 2016 SEHOUA Meeting
Slides from the 2016 SEHOUA Meeting have been posted. They include:
- Betsy Sears – “Young Kids, Old Bodies”
- Dr. Stout – “Drugs and Alcohol – The Landscape”
- Dr. Titcomb - “Red Cell Distribution Width (RDW): An Underappreciated Marker for Increased Mortality
- Mike Clift – “Motor Vehicle Reports and Driving Criticism Trends, Technology and Terminology”
- Dr. Greene - "Prostate Cancer: A Decade of Change"
- Dr. Dave Rengachary - “Advances in Multiple Sclerosis”
- Dr. Rooney – Genetics: A Discussion of How our Genes Impact Mortality”
- Ron Schaber, Philip R. Murphy and Greg Brandner - “Big Data Today and Tomorrow – the drive toward fully underwritten pricing”
Medical Marijuana for the Treatment of Multiple Sclerosis
“From Pariah to Prescription” was the title of a review that appeared some years ago on the possible medical use of marijuana. What then seemed utopian and provocative has now become reality! A recently published comprehensive meta-analysis came to the conclusion that the muscle relaxant and analgesic effects of THC in cases of multiple sclerosis (MS) were well documented.